MY PICK IS ELN

[kingofthehill]

Thanks Spike i always value your TA .. let me know after the close what you see

[lak]

Well there ya go gang!

[lak]

Congrats guys.

As Fat Albert says, "Hey, hey, hey, who want's to play!?" And that would be me.

Yep, ELN has done it! It's busted that resistance. The patient believers get their rewards, and there will be LOTS of money flowing in to this in the months ahead I suspect. Some of it will be mine!

and ah........ mine too I think........ should have held it when I had it back a bit ago........ will jump in there again!
Congrats!

[spikefader]

OK, I'm in at 9.15. I'm anticipating a runaway gap here and will use a 4.5% stop on it.
Here's the chart:

[Websman]

Welcome to the club Spike! It's good to know that your are now a fellow Elanian.

[kingofthehill]

I agree with most of this timeline

Goodbody Ireland - Elan - Tysabri data: an infusion of confiden
2005-08-10 03:12 (New York)


Elan and Biogen Idec yesterday announced that no new cases of PML had been
found in the recently completed review of MS patients on Tysabri who presented
for monitoring - 91% of the patient population. The review included patients
receiving Tysabri under prescription, where necessary. The review of patients
being treated for Crohn’s and rheumatoid arthritis should be completed by the
end of summer.

Elan and Biogen Idec plan to submit the safety data, two-year Phase II data and
a revised label to the FDA by late summer/early fall. We believe that the
compiled data will then be assessed by an advisory committee, which could take
two to three months, allowing for the return of the drug to the market in early
2006.

Both companies re-iterated that they are already taking preliminary steps to
restart clinical trials in MS. When announced during Q2’05 results late last
month, we anticipated that this meant a lack of PML in the patient cohort. In
addition, however, we believe it shows the companies’ confidence in the return
of Tysabri to the market and the FDA’s willingness to allow administration of
the drug to be resumed.

With the safety profile more secure and benefits quantified (Phase III, 2-year
data now available), we believe that the FDA will now look for: (i) an
understanding of the mechanism of PML development and from that a protocol for
identification of those potentially at risk; (ii) a procedure for the diagnosis
of PML at its early stages (the companies consider this will not be a
pre-requisite to Tysabri’s return); (iii) a regular screening protocol for
patients on Tysabri for signs of PML; and (iv) an established treatment
protocol should PML be detected.

These issues have been highlighted by Elan and Biogen Idec since the start of
the review process in March. Given the resources dedicated not only to
screening the Tysabri-treated patients but also reviewing all information on
PML, we believe that the development of the above framework is well advanced,
giving us comfort that the drug can return to the market by early 2006

The lower the risk, higher the benefit, the less restrictive the labelling,
which, we believe, increases the potential for a stronger return to market as
an MS treatment (possible requirements for regular screening may restrict use
in Crohn’s and RA). Given yesterday’s announcement, therefore, we have
increased our Tysabri projections to $257m in 2006 from $239m, with it now
peaking at $1.92bn in 2009 (formerly $1.77bn).

Newsflow is now critical and we expect the next announcements to be on: (i)
completion of the Crohn’s and RA review (September); (ii) submission of data to
the US and European authorities (Q3/Q4’05); (iii) the establishment of an
advisory committee (Q4’05); (iv) progress on clinical trial resumption (Q4’05);
followed by (v) regulatory decision (?).

Given the positive announcement on the MS patient safety review and its
implications not only on the return of Tysabri to the market, but also the
strength of that return, we are retaining our Buy recommendation on Elan with
an increased price target of $11.15 (previously $10.00). Although one-stage
closer to the return of Tysabri, we still caution that the stock remains a high
risk, speculative play until Tysabri completes the FDA review process and a
regulatory decision is made on its progress.

Provider ID: 87612988
-0- Aug/10/2005 7:12 GMT

[spikefader]

Back into stalk mode again for this evil thang. So much for runaway gap....

[Websman]

Back into stalk mode again for this evil thang. So much for runaway gap....

I'll keep holding, since I'm in at $6.89.

[skiracer]

I think that anything that happens with this stock right now comes strictly off the newswire. That most recent release the other day was buying on the news an on hope. The speculators and momo guys had a field day with it and look to be taking some of their gains off the table. It might turn out to be a great gamble, an I hope it does for you guys holding it, but it still looks like a gamble to me. The other day it wasn't able to hold the big run up after the explosive gap up in the pre-market and closed off it's highs for the day. Now the guys that got in on that one early and were holding to see if it kept going off are realizing that it's not and are taking back their money and waiting for the next news release. It would have been nice to take some of those gains at it's high that day and turned them back into more stock at the lows today if you really liked it that much. It didn't show any strength today and closed right at it's low of the day. Now the psychological game starts an I would bet that traders still holding positions in it are questioning why they didn't take some profit and what to do now. Once they get into that mode they really begin to look to protect their positions and money an are prone to exit at the slightest provocation, mainly any further drop, which might be good for it could provide a decent entry if it goes below 8 or lower again and would be a good time to throw the dice again.

[skiracer]

Trading on the news today again. Almost jumped on this one for a daytrade just because of the news break.



Had to include this little tidbit on SIRI and Richard Simmons. I'll definitely want to listen to him.

[jiesen]

Trading on the news today again. Almost jumped on this one for a daytrade just because of the news break.



Had to include this little tidbit on SIRI and Richard Simmons. I'll definitely want to listen to him.

according to the nutjobs on the Yahoo! boards, WYE is the potential ELN suitor... sounds to me like its just bullshit though.

[skiracer]

Jiesen,
Briefing.com feels the same way but everytime something comes across the wire suggesting this or that the stock gets a big play and afterwards pulls back. It was below 8 yesterday after the news and the big gap up from the other day and this item pushed it right back up over 8 again.
It looks like a good business to start a few rumors and buy into it. Like you I think all of it's just press releases and BS.

[Thomrich]

Greetings,

I know zero about ELN,yet I took the bait and played the gap.In at 8.04,was the lod for about 5sec.Im gonna hold till 7.61,hope the bulls come back.

Spike how do you like this gap fill,or would I be better off not knowing?

cordially Tom

[spikefader]

Greetings,

I know zero about ELN,yet I took the bait and played the gap.In at 8.04,was the lod for about 5sec.Im gonna hold till 7.61,hope the bulls come back.

Spike how do you like this gap fill,or would I be better off not knowing?

cordially Tom

lol, you probably don't want to hear it! heh.

Bearish on it with the channel turn down on the daily and the failure of gap support. Not acting bullishly at all. I note that the gap up the other day stopped dead in it's 100EMA tracks and it was a whimpy bull for new entries like mine the other day. This action is exactly why I love tight stops, when I'm wrong I am usually wrong big I won't be surprised to see it back down at 3.00. Good luck with it!

[New-born baby]

Blasphemy!

I won't be surprised to see it back down at 3.00. Good luck with it!

What kind of blasphemy is this??!! IN "church" no less!